Table 1 Epidemiological and clinical data of patients with CR-KP and CS-KP isolates
CR-KP | CS-KP | p-value | |
|---|---|---|---|
N = 28 | N = 14 | ||
Mean age (SD) | 62.93 (+/- 14.491) | 69.62 (+/- 16.717) | 0.186 |
Male sex | 18 (64.3 %) | 7 (50 %) | 0.508 |
Site of isolation | |||
Urine | 10 (35.7 %) | 9 (64.3 %) | 0.107 |
Blood culture | 6 (21.4 %) | 2 (14.3 %) | 0.697 |
Surgical wound | 4 (14.3 %) | 1 (7.1 %) | 0.650 |
Abdominal samples | 3 (10.7 %) | 0 | 0.539 |
Respiratory samples | 4 (14.3 %) | 1 (7.1 %) | 0.643 |
Others | 1 (3.6 %) | 1 (7.1 %) | 1 |
Length of stay before acquisition (SD) | 28.43 (+/- 31.319) | 20.14 (+/- 31.705) | 0.430 |
Overall mortality (related CR- or CS-KP)a | 35 % [7/20] | 11.11 % [1/9] | 0.371 (0.280) |
(20 % [4/20]) | (0) | ||
ICU acquisition | 9 (32.1 %) | 0 | 0.019* |
Previous antibiotic therapy (treatment) | |||
Penicillins/Betalactamase Inhibitor | 8 (28.6 %) | 2 (14.3 %) | 0.451 |
Carbapenems | 14 (50 %) | 3 (21.4 %) | 0.102 |
Third generation cephalosporins/Monobactams | 2 (7.1 %) | 1 (7.1 %) | 1 |
Fluoroquinolones | 4 (14.3 %) | 3 (21.4 %) | 0.668 |
Trimethoprim-sulfamethoxazole | 0 | 2 (14.3 %) | 0.106 |
None | 0 | 3 (21.4 %) | 0.032* |
Treatment | |||
Penicillins/Betalactamase Inhibitor | 1 (3.6 %) | 0 | 1 |
Carbapenems | 3 (10.7 %) | 7 (50 %) | 0.008* |
Carbapenems + Amikacin | 1 (3.6 %) | 1 (7.1 %) | 1 |
Tigecycline | 6 (21.4 %) | 1 (7.1 %) | 0.392 |
Tigecycline + Amikacin | 1 (3.6 %) | 0 | 1 |
Aminoglycosides | 1 (3.6 %) | 0 | 1 |
Colistin | 4 (14.3 %) | 0 | 0.283 |
Fosfomycin | 1 (3.6 %) | 0 | 1 |
None | 1 (3.6 %) | 0 | 1 |